Dana Broussard-Perry, MD
Allergy · Orlando, FLNPI 1306870530
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.3% of the total across 341 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations.
Across 341 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$804
- Optinose US, Inc.$789
- Kaleo, Inc.$468
- plus $2K from 23 others
What the payments were for
- Consulting fees$6988%
- Food & beverage$7,50591%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 43 | $1,777 |
| AstraZeneca | 44 | $1,247 |
| Regeneron Healthcare Solutions, Inc. | 42 | $1,112 |
| GSK | 47 | $804 |
| Optinose US, Inc. | 41 | $789 |
| Kaleo, Inc. | 28 | $468 |
| Genentech USA, Inc. | 11 | $347 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $340 |
| Novartis | 12 | $248 |
| Amgen | 9 | $248 |
| Grifols USA, LLC | 8 | $140 |
| CSL Behring | 5 | $111 |
| Pfizer | 4 | $71 |
| Sanofi-aventis U.S. LLC | 3 | $58 |
| Hikma Pharmaceuticals USA | 3 | $56 |
| Pharming Healthcare, Inc. | 3 | $52 |
| Alk-abello, Inc | 4 | $51 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $48 |
| Greer Laboratories, Inc. | 2 | $47 |
| AbbVie | 2 | $45 |
| Biocryst US Sales Co., LLC | 2 | $43 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Merck | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Circassia Inc. | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $14 |
| LEO Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,220 in reported general payments places this provider in the 75th percentile of 56 allergy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 26 | $96,124 |
| Azelastine Hcl | 33 | $1,198 |
| Fluticasone Propionate | 24 | $413 |
| Ipratropium Bromide | 13 | $322 |
| Montelukast Sodium | 34 | $317 |
| Levocetirizine Dihydrochloride | 16 | $147 |
Paid to pharmacies, not to this prescriber.
Other allergy in Orlando
- Boyce HornbergerOrlando$6K
- Aishah AliOrlando$577
- Jose AndradeOrlando$181
- Miguel LanzCoral Gables$778K
- Brett StanalandNaples$575K
- David RoseEglin Afb$253K
- Pavana BeerelliRockledge$61K
- Hugh WindomSarasota$37K
- Patrick de MarcoOrange Park$23K
- Mark MinorMelbourne$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.